Vaccination of chimpanzees against infection by the hepatitis C virus - PubMed (original) (raw)
Vaccination of chimpanzees against infection by the hepatitis C virus
Q L Choo et al. Proc Natl Acad Sci U S A. 1994.
Abstract
A high incidence of community-acquired hepatitis C virus infection that can lead to the progressive development of chronic active hepatitis, liver cirrhosis, and primary hepatocellular carcinoma occurs throughout the world. A vaccine to control the spread of this agent that represents a major cause of chronic liver disease is therefore needed. Seven chimpanzees (Pan troglodytes) have been immunized with both putative envelope glycoproteins [E1 (gp33) and E2 (gp72)] that were copurified from HeLa cells infected with a recombinant vaccinia virus expression vector. Despite the induction of a weak humoral immune response to these viral glycoproteins in experimentally infected chimpanzees, a strong humoral immune response was obtained in all vaccines. The five highest responders showed complete protection against an i.v. challenge with homologous hepatitis C virus 1. The remaining two vaccines became infected, but both infection and disease may have been ameliorated in comparison with four similarly challenged control chimpanzees, all of which developed acute hepatitis and chronic infections. These results provide considerable encouragement for the eventual control of hepatitis C virus infection by vaccination.
Similar articles
- Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, Davis HL, Emerson SU, Purcell RH, Bukh J. Forns X, et al. Hepatology. 2000 Sep;32(3):618-25. doi: 10.1053/jhep.2000.9877. Hepatology. 2000. PMID: 10960458 - Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees.
Esumi M, Rikihisa T, Nishimura S, Goto J, Mizuno K, Zhou YH, Shikata T. Esumi M, et al. Arch Virol. 1999;144(5):973-80. doi: 10.1007/s007050050559. Arch Virol. 1999. PMID: 10416378 - Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.
Bukh J, Forns X, Emerson SU, Purcell RH. Bukh J, et al. Intervirology. 2001;44(2-3):132-42. doi: 10.1159/000050040. Intervirology. 2001. PMID: 11509874 Review. - CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, Connors M, Feinstone SM, Major ME. Puig M, et al. Hepatology. 2006 Sep;44(3):736-45. doi: 10.1002/hep.21319. Hepatology. 2006. PMID: 16941702 - Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
Houghton M. Houghton M. Immunol Rev. 2011 Jan;239(1):99-108. doi: 10.1111/j.1600-065X.2010.00977.x. Immunol Rev. 2011. PMID: 21198667 Review.
Cited by
- Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.
Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cattaneo R. Reyes-del Valle J, et al. J Virol. 2012 Nov;86(21):11558-66. doi: 10.1128/JVI.01776-12. Epub 2012 Aug 15. J Virol. 2012. PMID: 22896607 Free PMC article. - Chimpanzee susceptibility to hepatitis C virus infection correlates with presence of Pt-KIR3DS2 and Pt-KIR2DL9: paired activating and inhibitory natural killer cell receptors.
Abi-Rached L, Guethlein LA, Norman PJ, Parham P. Abi-Rached L, et al. Immunogenetics. 2015 Oct;67(10):625-8. doi: 10.1007/s00251-015-0863-0. Epub 2015 Aug 12. Immunogenetics. 2015. PMID: 26260270 Free PMC article. - Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.
Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, Rice CM, Feinstone SM, Major ME. Fernandez J, et al. J Virol. 2004 Sep;78(18):9782-9. doi: 10.1128/JVI.78.18.9782-9789.2004. J Virol. 2004. PMID: 15331711 Free PMC article. - Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
Bailey JR, Barnes E, Cox AL. Bailey JR, et al. Gastroenterology. 2019 Jan;156(2):418-430. doi: 10.1053/j.gastro.2018.08.060. Epub 2018 Sep 27. Gastroenterology. 2019. PMID: 30268785 Free PMC article. Review. - Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.
Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, Pezzanera M, Ercole BB, McKeating J, Yagnik A, Lahm A, Tramontano A, Cortese R, Nicosia A. Roccasecca R, et al. J Virol. 2003 Feb;77(3):1856-67. doi: 10.1128/jvi.77.3.1856-1867.2003. J Virol. 2003. PMID: 12525620 Free PMC article.
References
- J Med Primatol. 1988;17(5):235-46 - PubMed
- Semin Liver Dis. 1986 Feb;6(1):56-66 - PubMed
- Science. 1989 Apr 21;244(4902):359-62 - PubMed
- Science. 1989 Apr 21;244(4902):362-4 - PubMed
- Lancet. 1989 Sep 30;2(8666):797 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical